Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease.

Endocrinol Metab (Seoul) · 2024 · PMC11375300 · PMID 39086276

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Notably, an increasing trend in the prescription of NRDA DPP4 inhibitors was observed from 2012 to 2018 ( Supplemental Fig.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.